- Home
- GAM vs CDNA Comparison
GAM vs CDNA Comparison
Compare GAM & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAM
- CDNA
- Stock Information
- Founded
- GAM 1927
- CDNA 1998
- Country
- GAM United States
- CDNA United States
- Employees
- GAM N/A
- CDNA N/A
- Industry
- GAM Investment Managers
- CDNA Medical Specialities
- Sector
- GAM Finance
- CDNA Health Care
- Exchange
- GAM Nasdaq
- CDNA Nasdaq
- Market Cap
- GAM 1.2B
- CDNA 1.0B
- IPO Year
- GAM N/A
- CDNA 2014
- Fundamental
- Price
- GAM $51.64
- CDNA $15.39
- Analyst Decision
- GAM
- CDNA Buy
- Analyst Count
- GAM 0
- CDNA 7
- Target Price
- GAM N/A
- CDNA $30.33
- AVG Volume (30 Days)
- GAM 20.1K
- CDNA 1.0M
- Earning Date
- GAM 01-01-0001
- CDNA 04-30-2025
- Dividend Yield
- GAM 5.74%
- CDNA N/A
- EPS Growth
- GAM N/A
- CDNA N/A
- EPS
- GAM 11.67
- CDNA 1.07
- Revenue
- GAM N/A
- CDNA $346,421,000.00
- Revenue This Year
- GAM N/A
- CDNA $13.28
- Revenue Next Year
- GAM N/A
- CDNA $15.13
- P/E Ratio
- GAM $3.95
- CDNA $14.29
- Revenue Growth
- GAM N/A
- CDNA 25.92
- 52 Week Low
- GAM $37.32
- CDNA $7.42
- 52 Week High
- GAM $46.48
- CDNA $34.84
- Technical
- Relative Strength Index (RSI)
- GAM 60.34
- CDNA 38.88
- Support Level
- GAM $51.08
- CDNA $14.09
- Resistance Level
- GAM $51.98
- CDNA $18.71
- Average True Range (ATR)
- GAM 0.84
- CDNA 1.01
- MACD
- GAM 0.26
- CDNA -0.25
- Stochastic Oscillator
- GAM 88.38
- CDNA 24.03
About GAM General American Investors Inc.
General American Investors Co Inc is a closed-end, diversified management investment company. The primary investment objective of the company is long-term capital appreciation through investment in companies with above-average growth potential. It focuses on equity securities with growth potential at reasonable valuations.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.